S&P Futures
5,913.25 +7.25 (+0.12%) Dow Futures
43,571.00 +53.00 (+0.12%) Nasdaq Futures
20,514.25 +30.75 (+0.15%) Russell 2000 Futures
2,296.70 +5.50 (+0.24%) Crude Oil
69.32 +0.10 (+0.14%) Gold
2,742.30 +12.30 (+0.45%)
Crinetics Pharmaceuticals, Inc. (CRNX)
After hours:
| Previous Close | 58.92 |
| Open | 58.91 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 58.40 - 59.80 |
| 52 Week Range | 25.75 - 59.80 |
| Volume | |
| Avg. Volume | 676,351 |
| Market Cap | 5.32B |
| Beta (5Y Monthly) | 0.64 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.76 |
| Earnings Date | Nov 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 71.31 |
GuruFocus.comState Street Corp's Strategic Acquisition in Crinetics Pharmaceuticals
On September 30, 2024, State Street Corp made a significant addition to its investment portfolio by acquiring 2,838,484 shares of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX). This transaction, executed at a price of $51.10 per share, marks a notable expansion in State Street Corp's holdings within the biotechnology sector. The addition of these shares has increased the firm's total stake in Crinetics Pharmaceuticals to a substantial 3.60% of its portfolio, reflecting a strategic move to bolster its presence in the biotech industry.
GlobeNewswireCrinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024
SAN DIEGO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Tuesday, November 12 @ 4:30 p.m. ET Domestic: 1-800-579-2543International: 1-785-424-1789Conference ID: CRNXQ3 Participants can use
